<DOC>
	<DOCNO>NCT02970786</DOCNO>
	<brief_summary>The primary objective trial test new radio tracer 68Ga-NODAGA-E [ c ( RGDyK ) ] 2 PET image angiogenesis . The tracer potential identifying tumor high level angiogenesis , one cancer hallmark . Furthermore , tracer potentially use early response assessment anti-angiogenic treatment . This first-in-man study test radio tracer cancer patient . Safety , biodistribution dosimetry evaluate repeated PET imaging ( 10 minute , 1 hour 2 hour post injection ) .</brief_summary>
	<brief_title>Phase I Trial : 68Ga-NODAGA-E ( cRGDyK ) 2 Positron Emission Tomography Imaging Angiogenesis Primary Metastatic Tumor Lesions Humans</brief_title>
	<detailed_description>The primary objective trial test new radio tracer 68Ga-NODAGA-E [ c ( RGDyK ) ] 2 PET image angiogenesis . The tracer potential identifying tumor high level angiogenesis , one cancer hallmark . Furthermore , tracer potentially use early response assessment anti-angiogenic treatment . This first-in-man study test radio tracer cancer patient . Safety , biodistribution dosimetry evaluate repeated PET imaging ( 10 minute , 1 hour 2 hour post injection ) . The primary end point safety , biodistribution dosimetry 68Ga-NODAGA-E [ c ( RGDyK ) ] 2 . In addition , quantitative uptake 68Ga-NODAGA-E [ c ( RGDyK ) ] 2 compare expression integrin αvβ3 measure directly tumor tissue obtain surgery biopsy . The study monitor evaluated accordance principle Good Clinical Practice ( GCP ) .</detailed_description>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>Diagnosed neuroendocrine cancer , breast cancer ovarian cancer Capable understand give full inform consent Pregnancy Lactation Obesity ( weight 140 kg ) Claustrophobia</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>